In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Open Access
- 18 June 2022
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 16 (15) , 2810-2822
Abstract
Prognostic biomarkers for prostate cancer are needed to improve prediction of disease course and guide treatment decisions. However, biomarker development is complicated by the common multifocality and heterogeneity of the disease. We aimed to determine the prognostic value of candidate biomarkers transcriptional regulator ERG and related ETS family genes, while considering tumor heterogeneity. In a multisampled, prospective, and treatment‐naïve radical prostatectomy cohort from one tertiary center (2010–2012, median follow‐up 8.1 years), we analyzed ERG protein (480 patients; 2047 tissue cores), and RNA of several ETS genes in a subcohort (165 patients; 778 fresh‐frozen tissue samples). Intra‐ and interfocal heterogeneity was identified in 29% and 33% (ERG protein) and 39% and 27% (ETS RNA) of patients, respectively. ERG protein and ETS RNA was identified exclusively in a nonindex tumor in 31% and 32% of patients, respectively. ERG protein demonstrated independent prognostic value in predicting biochemical (P = 0.04) and clinical recurrence (P = 0.004) and appeared to have greatest prognostic value for patients with Grade Groups 4–5. In conclusion, when heterogeneity is considered, ERG protein is a robust prognostic biomarker for prostate cancer.Keywords
Funding Information
- Helse Sør-Øst RHF (2017045, 2019016, 2020063)
- Kreftforeningen (208197)
- Norges Forskningsråd (262529/F20, Toppforsk‐250993)
This publication has 42 references indexed in Scilit:
- Intraductal carcinoma of the prostate: Precursor or aggressive phenotype of prostate cancer?The Prostate, 2012
- The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysisCancer Epidemiology, Biomarkers & Prevention, 2012
- FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancerGenes, Chromosomes and Cancer, 2011
- Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cellsGenes & Development, 2011
- Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practiceLaboratory Investigation, 2011
- Testing mutual exclusivity of ETS rearranged prostate cancerLaboratory Investigation, 2011
- Endogenous Control Genes in Prostate Cells: Evaluation of Gene Expression Using ‘Real-Time’ Quantitative Polymerase Chain ReactionMedical Principles and Practice, 2010
- Recurrent gene fusions in prostate cancerNature Reviews Cancer, 2008
- Morphological features of TMPRSS2–ERG gene fusion prostate cancerThe Journal of Pathology, 2007
- TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN LesionsNeoplasia, 2006